Healius Limited (AU:HLS) has released an update.
Healius Limited has reported a solid financial performance for FY24, with a 6.1% increase in business-as-usual revenue to $1.74 billion, and significant earnings with an underlying EBITDA of $346.6 million and EBIT of $65.4 million. Despite a decrease in Covid-related revenues, the company saw growth in its Pathology and Imaging segments, and Agilex Biolabs showed strong growth with revenue up by 20.8% and EBITDA more than doubling. Healius continues to navigate challenges such as inflationary pressures and government rebate issues while investing in strategic initiatives for future growth.
For further insights into AU:HLS stock, check out TipRanks’ Stock Analysis page.
